The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-growing ...

AstraZeneca and Sanofi are leading the charge here with nirsevimab, a long-acting antibody designed to provide passive protection to infants through their first RSV season with a single dose.

The Fresno County Department of Public Health has confirmed the first pediatric flu and RSV deaths of the 2024-2025 ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Health officials have confirmed the first pediatric flu and RSV death of the 2024-25 respiratory virus season in Fresno County.

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine evaluation. A 2023–24 vaccine effectiveness analysis of immunocompetent adults ...

In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...

Coinfection with RSV, REV, and MPV was significantly associated with treatment failure and prolonged treatment in children with viral LRTIs on respiratory support.